JP2022520859A5 - - Google Patents
Info
- Publication number
- JP2022520859A5 JP2022520859A5 JP2021548200A JP2021548200A JP2022520859A5 JP 2022520859 A5 JP2022520859 A5 JP 2022520859A5 JP 2021548200 A JP2021548200 A JP 2021548200A JP 2021548200 A JP2021548200 A JP 2021548200A JP 2022520859 A5 JP2022520859 A5 JP 2022520859A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rorγ
- composition according
- pharmaceutical composition
- jte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808231P | 2019-02-20 | 2019-02-20 | |
| US62/808,231 | 2019-02-20 | ||
| US201962881890P | 2019-08-01 | 2019-08-01 | |
| US62/881,890 | 2019-08-01 | ||
| US201962897202P | 2019-09-06 | 2019-09-06 | |
| US62/897,202 | 2019-09-06 | ||
| US201962903595P | 2019-09-20 | 2019-09-20 | |
| US62/903,595 | 2019-09-20 | ||
| US202062959607P | 2020-01-10 | 2020-01-10 | |
| US62/959,607 | 2020-01-10 | ||
| PCT/US2020/019118 WO2020172467A1 (en) | 2019-02-20 | 2020-02-20 | Treatment for retinoic acid receptor-related orphan receptor ɣ (rorɣ)-dependent cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520859A JP2022520859A (ja) | 2022-04-01 |
| JP2022520859A5 true JP2022520859A5 (cg-RX-API-DMAC7.html) | 2023-02-28 |
Family
ID=72144161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548200A Pending JP2022520859A (ja) | 2019-02-20 | 2020-02-20 | レチノイン酸受容体関連オーファン受容体γ(RORγ)依存性がんのための治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220202811A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3927329A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022520859A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113710239A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020172467A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021149786A1 (en) * | 2020-01-24 | 2021-07-29 | Japan Tobacco Inc. | Methods of treating cancer using dihydropyrimidin-2-one compounds |
| AU2024267864A1 (en) * | 2023-05-09 | 2025-11-06 | 11949098 Canada Inc. | Inverse agonists of rar related orphan receptors (rors) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9629910B2 (en) * | 2011-03-22 | 2017-04-25 | The Brigham And Women's Hospital, Inc. | Use of Th9 cells and IL-9 for the treatment of melanoma |
| WO2012158784A2 (en) * | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| US9359315B2 (en) * | 2013-09-10 | 2016-06-07 | Arrien Pharmaceuticals Llc | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis |
| WO2015083130A1 (en) * | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
| SI3207043T1 (sl) * | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| CN107614062A (zh) * | 2015-03-12 | 2018-01-19 | 加利福尼亚大学董事会 | 用RORγ抑制剂治疗癌症的方法 |
| KR102702236B1 (ko) * | 2015-05-15 | 2024-09-04 | 오리진 온콜로지 리미티드 | Ror 감마 조절제로서의 치환된 테트라하이드로퀴놀리논 화합물 |
| US20240245633A1 (en) * | 2015-11-04 | 2024-07-25 | University Of Florida Research Foundation, Incorporated | ROR Gamma Agonists as Enhancers of Protective Immunity |
| WO2017127442A1 (en) * | 2016-01-18 | 2017-07-27 | The Regents Of The University Of California | Methods for treating cancer with rorgamma inhibitors |
-
2020
- 2020-02-20 WO PCT/US2020/019118 patent/WO2020172467A1/en not_active Ceased
- 2020-02-20 JP JP2021548200A patent/JP2022520859A/ja active Pending
- 2020-02-20 US US17/432,485 patent/US20220202811A1/en not_active Abandoned
- 2020-02-20 CN CN202080028000.6A patent/CN113710239A/zh active Pending
- 2020-02-20 EP EP20759521.6A patent/EP3927329A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7492002B2 (ja) | Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法 | |
| JP2024015120A5 (cg-RX-API-DMAC7.html) | ||
| RU2012147739A (ru) | Пероральные составы, содержащие аналоги цитидина, и способы их использования | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| JP2024527109A5 (cg-RX-API-DMAC7.html) | ||
| JP2022509262A5 (cg-RX-API-DMAC7.html) | ||
| Tewes et al. | Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study | |
| JP2022504468A5 (cg-RX-API-DMAC7.html) | ||
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| Engelsman et al. | Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an EORTC study. | |
| MX2023005695A (es) | Administracion de agonista de sting, inhibidores de puntos de control y radiacion. | |
| WO2023272831A1 (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| CN112741833A (zh) | 西达本胺及其衍生物的用途 | |
| Forouzesh et al. | Phase I, bioavailability, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies | |
| TWI813331B (zh) | β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途 | |
| AU2020255063B2 (en) | Combined use of A-nor-5α androstane compound drug and anticancer drug | |
| CN115869409A (zh) | Hdac抑制剂联合ar拮抗剂在抗乳腺癌中的用途 | |
| US8663711B2 (en) | Use of armillaridin for treating cancer | |
| RU2010139840A (ru) | Комбинация противораковых агентов | |
| JP2022504760A5 (cg-RX-API-DMAC7.html) | ||
| CN113082037B (zh) | 小分子组合物在制备治疗肝内胆管细胞癌药物中的应用 | |
| CN111728960B (zh) | 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用 | |
| US20040266704A1 (en) | Method comprising irinotecan for treatment of breast cancer | |
| SU731967A1 (ru) | Способ лечени воспалительных заболеваний легких | |
| Hofheinz et al. | Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle? |